Contact us: +91 9550333722 040 - 40102781
Structured search
India
Choose your country
Different countries will display different contents
Try our best to find the right business for you.
My chemicalbook

Welcome back!

HomeProduct name listBUCINDOLOL

BUCINDOLOL

BUCINDOLOL Structural

What is BUCINDOLOL?

Originator

Bucindolol hydrochloride,Bristol Myers (BMS)

The Uses of BUCINDOLOL

Antihypertensive.

Manufacturing Process

A solution of 2-cyanophenol (25.0 g, 0.21 mole), epichlorohydrin (117.0 g, 1.26 mole), and piperidine (10 drops) was stirred and heated at 115-120°C in an oil bath for 2 h. The reaction mixture was then concentrated (90/30 mm) to remove unreacted epichlorohydrin. The residue was diluted with toluene and taken to dryness twice to help remove the last traces of volatile material. The residual oil was dissolved in 263 ml of THF, and the solution stirred at 40- 50°C for 1 h with 263 ml of 1 N NaOH. The organic layer was separated and concentrated to give an oil which was combined with the aqueous phase. The mixture was extracted with CH2Cl2 and the extract dried (MgSO4) and concentrated to give 36.6 g (100%) of 2-[(2,3-epoxy)propoxy]benzonitrile as oil, which slowly crystallized to a waxy solid.
A mixture of gramine (120.0 g, 0.69 mole), 2-nitropropane (443 ml), and NaOH (28.8 g, 0.72 mole) was stirred and gradually heated to reflux under N2. After a 6.5 h reflux period, the reaction mixture was allowed to stand at room temperature overnight, and then diluted with 600 ml of 10% aqueous AcOH. The mixture was extracted with 1.5 l of Et2O and the organic layer washed with H2O (4x 500 ml). Concentration of the Et2O solution in vacuum gave an oil which was dissolved in 500 ml of 95% EtOH. This solution was diluted with 300 ml of H2O. After cooling, the yellow solid was collected on a filter to give 105.0 g (70%) of nitro intermediate, melting point 72-74°C. The nitro compound was dissolved in 1.3 L of 95% EtOH, and Raney nickel (70.0 g, EtOH-washed) and added. The mixture was heated to reflux, and a solution of 85% hydrazine hydrate (116.0 g, 2.3 mole) in 95% EtOH (110 ml) was added dropwise at a rate to maintain gentle reflux. The mixture was then heated at reflux for an additional 1.5 h, cooled, and filtered. Concentration of the filtrate gave crude product as a solid. A solution of the solid in 400 ml of EtOAc was diluted with 500 ml of (i-Pr)2O and cooled. The white, cottony solid which separated was collected on a filter to give 91.0 g (100%) of 2-(3- indolyl)-1,1-dimethylethylamine, melting point 122-126°C.
A solution of 2-[(2,3-epoxy)propoxy]benzonitrile (18.3 g, 0.10 mole) and 2- (3-indolyl)-1,1-dimethylethylamine (15.2 g, 0.08 mole), in 500 ml of abs. EtOH was stirred at reflux overnight. After concentration of the reaction mixture to approximately 200 ml and seeding, crude product began to precipitate. The mixture was then cooled and the precipitate separated by filtration to give 24.8 g of the free base form of the product, white solid, melting point 120-123°C. The crude solid was dissolved in 400 ml of boiling MeOH, and the solution was cooled with stirring, as a by-product 1,1’-[[1,1- dimethyl-2-(1H-indol-3-yl]ethyl]imino]bis-[3-(2-cyanophenoxy)-2-propanol] precipitated. The by-product was collected on a filter and air dried to give 2.2 g, of 2-[2-hydroxy-3-[[2-(3-indolyl)-1,1-dimethylethyl]amino]propoxy] benzonitrile, melting point 180-187°C.
In practice it is usually used as hydrochloride.

Therapeutic Function

Antihypertensive

Properties of BUCINDOLOL

Melting point: 185-187°
pka 8.86(at 25℃)

Safety information for BUCINDOLOL

Computed Descriptors for BUCINDOLOL

Related products of tetrahydrofuran

You may like

  • 1-Methyl-6-oxo-1,6-dihydropyridazine-3-carbonitrile 98%
    1-Methyl-6-oxo-1,6-dihydropyridazine-3-carbonitrile 98%
    99903-60-3
    View Details
  • 88491-46-7 98%
    88491-46-7 98%
    88491-46-7
    View Details
  • 1823368-42-8 98%
    1823368-42-8 98%
    1823368-42-8
    View Details
  • 2-(3-(tert-butyl)phenoxy)-2-methylpropanoic acid 1307449-08-6 98%
    2-(3-(tert-butyl)phenoxy)-2-methylpropanoic acid 1307449-08-6 98%
    1307449-08-6
    View Details
  • Ethyl 3-(furan-2-yl)-3-hydroxypropanoate 25408-95-1 98%
    Ethyl 3-(furan-2-yl)-3-hydroxypropanoate 25408-95-1 98%
    25408-95-1
    View Details
  • 2-Chloro-5-fluoro-1-methoxy-3-methylbenzene 98%
    2-Chloro-5-fluoro-1-methoxy-3-methylbenzene 98%
    1805639-70-6
    View Details
  • 1784294-80-9 98%
    1784294-80-9 98%
    1784294-80-9
    View Details
  • Lithium Clavulanate
    Lithium Clavulanate
    61177-44-4
    View Details
Statement: All products displayed on this website are only used for non medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.